Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avricore Health (AVCRF) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for Avricore Health (AVCRF) over the last 11 years, with Q3 2025 value amounting to $73.6 million.

  • Avricore Health's Shares Outstanding (Diluted Average) fell 411.86% to $73.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.6 million, marking a year-over-year decrease of 411.86%. This contributed to the annual value of $73.3 million for FY2024, which is 70.66% down from last year.
  • According to the latest figures from Q3 2025, Avricore Health's Shares Outstanding (Diluted Average) is $73.6 million, which was down 411.86% from $73.1 million recorded in Q2 2025.
  • In the past 5 years, Avricore Health's Shares Outstanding (Diluted Average) ranged from a high of $77.2 million in Q2 2024 and a low of $71.8 million during Q4 2024
  • In the last 4 years, Avricore Health's Shares Outstanding (Diluted Average) had a median value of $74.2 million in 2023 and averaged $74.3 million.
  • As far as peak fluctuations go, Avricore Health's Shares Outstanding (Diluted Average) soared by 410.53% in 2024, and later tumbled by 532.46% in 2025.
  • Quarter analysis of 4 years shows Avricore Health's Shares Outstanding (Diluted Average) stood at $72.1 million in 2022, then rose by 1.44% to $73.1 million in 2023, then decreased by 1.81% to $71.8 million in 2024, then grew by 2.47% to $73.6 million in 2025.
  • Its last three reported values are $73.6 million in Q3 2025, $73.1 million for Q2 2025, and $71.8 million during Q4 2024.